Nautilus Biotechnology (NAUT) to Release Quarterly Earnings on Thursday

Nautilus Biotechnology (NASDAQ:NAUT) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Nautilus Biotechnology Price Performance

Shares of NAUT stock opened at $1.47 on Wednesday. The stock has a market cap of $184.57 million, a P/E ratio of -2.62 and a beta of 1.21. The company has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $2.27. Nautilus Biotechnology has a one year low of $1.47 and a one year high of $3.09.

Analyst Ratings Changes

Separately, The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $2.25 to $1.75 in a research note on Thursday, December 5th.

Institutional Investors Weigh In On Nautilus Biotechnology

A hedge fund recently raised its stake in Nautilus Biotechnology stock. Bank of America Corp DE raised its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 37.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 49,419 shares of the company’s stock after purchasing an additional 13,363 shares during the period. Bank of America Corp DE’s holdings in Nautilus Biotechnology were worth $83,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.